ArticleDigestive diseases and sciences2009
Endocan expression correlated with poor survival in human hepatocellular carcinoma.
Article in Digestive diseases and sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 81 citations in OpenAlex.
- Upregulation of endocan by Epstein-Barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma.PloS one · 2013Trial
- Melatonin for gastric cancer treatment: where do we stand?Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Serum resistin and the risk for hepatocellular carcinoma in diabetic patients.World journal of gastroenterology · 2023Review
- Prognostic and Diagnostic Value of Endocan in Kidney Diseases.International journal of nephrology · 2022Review
- Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma.World journal of hepatology · 2021Article
- Association of endocan expression with clinicopathological prognostic parameters in breast carcinoma.Cancer biomarkers : section A of Disease markers · 2021Article
- Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach.Frontiers in oncology · 2021Review
- Abdominal Tuberculosis Managed Surgically in the Late Phase: A Case Report.Journal of acute medicine · 2020Article
- Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas.Frontiers in medicine · 2020Review
- Endothelial cell-specific molecule-1 as an invasiveness marker for pituitary null cell adenoma.BMC endocrine disorders · 2019Article
- Endocan silencing induces programmed cell death in hepatocarcinoma.Oncology letters · 2017Article
- Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors.Medicine · 2017Article
- Endocan Measurement for Active Behçet Disease.Archives of rheumatology · 2017Article
- Article
- Endocan as a prognostic biomarker of triple-negative breast cancer.Breast cancer research and treatment · 2017Article
- Overexpression of Endothelial Cell-Specific Molecule 1 Correlates with Gleason Score and Expression of Androgen Receptor in Prostate Carcinoma.International journal of medical sciences · 2017Article
- Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression.International journal of medical sciences · 2017Article
- Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study.Journal of clinical laboratory analysis · 2016Article
- Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer.World journal of gastroenterology · 2016Observational
- Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.Endocrine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death in China. We aimed to first present the expression of endocan in HCC tissue and its correlation with the clinicopathological features and overall survival of patients with HCC after curative hepatectomy. Immunohistochemical detection of endocan, CD34, and vascular endothelial growth factor (VEGF) were performed on samples from 100 patients with HCC. Endocan protein was expressed in endothelium of HCC tissue in all specimens, but was not expressed in endothelium of pericarcinomatous liver tissue and normal liver tissue. Microvessel density (MVD) denoted by endocan (endocan-MVD) in HCC was correlated with microscopic venous invasion and VEGF expression (P < 0.05). Survival analysis showed that overall survival of patients was inversely associated with endocan-MVD (P < 0.01). Multivariate analysis showed that endocan-MVD was an independent prognostic marker for overall survival of HCC (P < 0.01). In conclusion, endocan-MVD was a significant factor to predict the prognosis of HCC patients after curative hepatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.